Pfizer's RSV candidate receives FDA special status

The US health authority will accelerate its review of US-based Pfizer’s vaccine against RSV after granting it the Breakthrough Therapy Designation.


Pfizer can look forward to a faster approval process for its vaccine against respiratory syncytial virus (RSV), as the US Food and Drug Administration (FDA) will fast-track its drug review, Bloomberg reports.

The FDA’s special status, known as the Breakthrough Therapy Designation, is meant to expedite the development and case processing of drugs that treat serious diseases. RSV is a common virus that usually only leads to flu-like symptoms but can cause serious lung infections. Some at risk individuals include the elderly, immunocompromised persons and infants.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs